MA32300B1 - Anticorps anti-facteur d humanises et utilisations de ceux-ci - Google Patents

Anticorps anti-facteur d humanises et utilisations de ceux-ci

Info

Publication number
MA32300B1
MA32300B1 MA33342A MA33342A MA32300B1 MA 32300 B1 MA32300 B1 MA 32300B1 MA 33342 A MA33342 A MA 33342A MA 33342 A MA33342 A MA 33342A MA 32300 B1 MA32300 B1 MA 32300B1
Authority
MA
Morocco
Prior art keywords
antibodies
factor antibodies
treatment
humanizing anti
factor
Prior art date
Application number
MA33342A
Other languages
Arabic (ar)
English (en)
Inventor
Robert F Kelley
Henry Lowman
Lookeren Campagne Menno Van
Arthur J Huang
Charles M Winter
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40999836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32300(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA32300B1 publication Critical patent/MA32300B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps anti-facteur d, leurs séquences d'acide nucléique et d'acides aminés, les cellules et vecteurs qui portent ces anticorps et leur production et leur utilisation dans la préparation de compositions et de médicaments pour le traitement de maladies et de troubles associés à une activation du complément excessive ou incontrôlée. Ces anticorps sont utiles pour le diagnostic, la prophylaxie et le traitement d'une maladie.
MA33342A 2008-04-28 2010-11-11 Anticorps anti-facteur d humanises et utilisations de ceux-ci MA32300B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4843108P 2008-04-28 2008-04-28
US4868908P 2008-04-29 2008-04-29
PCT/US2009/041785 WO2009134711A1 (fr) 2008-04-28 2009-04-27 Anticorps anti-facteur d humanisés et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA32300B1 true MA32300B1 (fr) 2011-05-02

Family

ID=40999836

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33342A MA32300B1 (fr) 2008-04-28 2010-11-11 Anticorps anti-facteur d humanises et utilisations de ceux-ci

Country Status (35)

Country Link
US (7) US8273352B2 (fr)
EP (3) EP3002295A1 (fr)
JP (2) JP5636359B2 (fr)
KR (2) KR101322027B1 (fr)
CN (2) CN102066419B (fr)
AR (2) AR071510A1 (fr)
AU (1) AU2009241348C1 (fr)
BR (1) BRPI0907701A2 (fr)
CA (2) CA2720853C (fr)
CL (2) CL2009001001A1 (fr)
CO (1) CO6331346A2 (fr)
CR (2) CR20170001A (fr)
CY (1) CY1116982T1 (fr)
DK (1) DK2283041T3 (fr)
EC (1) ECSP10010637A (fr)
ES (1) ES2552817T3 (fr)
HK (1) HK1245812A1 (fr)
HR (1) HRP20151259T1 (fr)
HU (1) HUE026349T2 (fr)
IL (3) IL208555A (fr)
MA (1) MA32300B1 (fr)
MX (2) MX2010011342A (fr)
MY (2) MY162350A (fr)
NZ (3) NZ588457A (fr)
PE (2) PE20140806A1 (fr)
PH (1) PH12014500519B1 (fr)
PL (1) PL2283041T3 (fr)
PT (1) PT2283041E (fr)
RS (1) RS54405B1 (fr)
RU (1) RU2488594C2 (fr)
SG (2) SG10201608305SA (fr)
SI (1) SI2283041T1 (fr)
TW (3) TWI558413B (fr)
WO (1) WO2009134711A1 (fr)
ZA (1) ZA201301709B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2500030E (pt) * 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
PL2907827T3 (pl) * 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
EP2558494B1 (fr) 2010-04-15 2018-05-23 AbbVie Inc. Protéines de liaison à la bêta amyloïde
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
JP6161541B2 (ja) * 2011-02-03 2017-07-12 ゾーマ テクノロジー リミテッド 細菌中の機能的タンパク質発現を向上させるための方法および物質
WO2012135050A2 (fr) 2011-03-25 2012-10-04 Soft Machines, Inc. Fragments de mémoire permettant de prendre en charge une exécution de blocs de codes en utilisant des cœurs virtuels instanciés par des moteurs partitionnables
US20150039859A1 (en) * 2011-11-22 2015-02-05 Soft Machines, Inc. Microprocessor accelerated code optimizer
SI2898086T1 (sl) 2012-09-19 2019-03-29 F. Hoffmann-La Roche Ag Načini in sestavki za preprečevanje napačnega vključevanja norlevcina v beljakovine
CA2891686A1 (fr) 2012-12-18 2014-06-26 Novartis Ag Compositions et procedes qui utilisent une etiquette peptidique qui se lie au hyaluronane
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
KR102083390B1 (ko) 2013-03-15 2020-03-02 인텔 코포레이션 네이티브 분산된 플래그 아키텍처를 이용하여 게스트 중앙 플래그 아키텍처를 에뮬레이션하는 방법
WO2014197885A2 (fr) 2013-06-07 2014-12-11 Duke University Inhibiteurs du facteur h du complément
WO2015006507A1 (fr) 2013-07-09 2015-01-15 Annexon, Inc. Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
CA2926812A1 (fr) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methodes pour empecher la mort des cellules photoreceptrices ou reduire le nombre de cellules photoreceptrices mortes
KR20160147855A (ko) * 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
EP3160990A2 (fr) 2014-06-25 2017-05-03 Novartis AG Compositions et procédés pour protéines à action longue
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MX2018005226A (es) 2015-10-30 2019-04-29 Genentech Inc Formulaciones de anticuerpo anti-factor d.
ES2904553T3 (es) * 2015-10-30 2022-04-05 Hoffmann La Roche Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
AU2016344146A1 (en) 2015-10-30 2018-05-10 Genentech, Inc. Methods of measuring Factor D activity and potency of Factor D inhibitors
SG11201803356SA (en) 2015-10-30 2018-05-30 Genentech Inc Anti-htra1 antibodies and methods of use thereof
EP3368074A2 (fr) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anticorps et conjugués anti-facteur d
CN115260310B (zh) * 2015-11-24 2025-02-25 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3405577B8 (fr) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions et procédés pour inhiber le facteur d
CN107043422B (zh) * 2016-01-28 2022-01-04 成都康弘生物科技有限公司 抗补体因子D的人源化Fab和人源化抗体及其用途
CA3022673A1 (fr) * 2016-05-02 2017-11-09 Prothena Biosciences Limited Immunotherapie anti-tau
WO2018136827A1 (fr) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d
KR20190129859A (ko) 2017-02-10 2019-11-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-d 인자 항체 및 그의 용도
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华（上海）生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US12172106B2 (en) 2018-08-09 2024-12-24 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2023114763A1 (fr) 2021-12-13 2023-06-22 Annexon, Inc. Anticorps anti-facteur du complément c1q à bras de liaison uniques et leurs utilisations
WO2025208782A1 (fr) * 2024-04-02 2025-10-09 Linno (Hangzhou) Pharmaceuticals Inc. Fragments d'anticorps se liant au facteur d du complément et leurs utilisations

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
CA2116774C (fr) 1991-09-19 2003-11-11 Paul J. Carter Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
EP0751787B1 (fr) 1994-03-23 2005-01-12 Alexion Pharmaceuticals, Inc. Procede permettant de reduire les dysfonctionnements des systemes immunitaire et hemostatique pendant la circulation extra-corporelle
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US5897475A (en) 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
WO2000036102A2 (fr) 1998-12-16 2000-06-22 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
WO1999046281A2 (fr) 1998-03-10 1999-09-16 Genentech, Inc. Nouveaux polypeptides et acides nucleiques les codant
WO1999040100A1 (fr) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 proteines humaines secretees
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
WO1999027098A2 (fr) 1997-11-21 1999-06-03 Genentech, Inc. Antigenes apparentes a a33 et leurs utilisations pharmacologiques
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
EP1007092B1 (fr) 1997-08-26 2006-08-09 Amgen Fremont Inc. Procede d'inhibition d'activation de complement par la voie alterne
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
JP4437192B2 (ja) 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
IL143031A0 (en) 1998-12-22 2002-04-21 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CA2362427A1 (fr) 1999-03-08 2000-09-14 Genentech, Inc. Compositions et methodes de traitement des maladies immunitaires
ATE500328T1 (de) 1999-03-11 2011-03-15 Merck Serono Sa Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1234030A4 (fr) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 proteines secretees humaines
EP1666494A1 (fr) 1999-12-01 2006-06-07 Genentech, Inc. Polypeptides secretés et transmembranaires et acides nucléiques les codant
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
PT1265929E (pt) 2000-03-23 2009-10-15 Genentech Inc Inibidores anti-c2/c2a de activação complementar
DK2026073T3 (en) 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
CA2412211A1 (fr) 2000-06-23 2002-01-03 Genetech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
EP2113516B1 (fr) 2000-10-10 2014-05-21 Genentech, Inc. Anticorps contre C5 inhibant l'activation de type II des cellules endothéliales
TR200300478T2 (tr) 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
US20040077575A1 (en) 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
CA2457461C (fr) 2001-08-17 2013-12-24 Tanox, Inc. Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
WO2004022594A2 (fr) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Methodes et composes d'immunomodulation
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (fr) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associes a des reponses a des douleurs neuropathiques
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
AU2005314461B2 (en) 2004-11-18 2012-02-02 The Rockefeller University Methods and compositions for treating ocular disorders
WO2006071856A2 (fr) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulines comprenant principalement une glycoforme man5glcnac2
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
CA2725709A1 (fr) 2005-06-08 2006-12-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatio N Genes de predisposition a une degenerescence maculaire liee a l'age (dmla) sur le chromosome 10q26
CA2625206C (fr) 2005-10-08 2021-12-07 Potentia Pharmaceuticals, Inc. Compstatine et analogues de celle-ci pour des troubles de la vue
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
WO2008140793A2 (fr) 2007-05-11 2008-11-20 Tufts Medical Center Polynucléotides associés à une dégénérescence maculaire liée à l'âge et procédés d'évaluation d'un risque de patient
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2009146204A1 (fr) 2008-04-18 2009-12-03 Tufts Medical Center Polymorphismes associés à la dégénérescence maculaire liée à l’âge et procédés d’évaluation du risque pour un patient
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CA2740242A1 (fr) 2008-11-05 2010-05-14 Genentech, Inc. Polymorphismes genetiques dans la degenerescence maculaire liee a l'age
US20120115925A1 (en) 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
WO2010085542A2 (fr) 2009-01-23 2010-07-29 Novartis Ag Biomarqueurs associés à la dégénérescence maculaire liée à l'âge (dmla)
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP5651527B2 (ja) * 2011-05-02 2015-01-14 沖電気工業株式会社 無線端末装置、無線通信システム、プログラムおよび無線通信方法

Also Published As

Publication number Publication date
AU2009241348C1 (en) 2013-03-28
WO2009134711A1 (fr) 2009-11-05
AU2009241348A1 (en) 2009-11-05
EP3235829B1 (fr) 2019-05-22
CA2908470A1 (fr) 2009-11-05
JP2011521623A (ja) 2011-07-28
MX2018013087A (es) 2020-09-02
US20090269338A1 (en) 2009-10-29
CA2720853A1 (fr) 2009-11-05
NZ621103A (en) 2015-10-30
PL2283041T3 (pl) 2016-01-29
CR20170001A (es) 2017-08-10
ES2552817T3 (es) 2015-12-02
HK1147503A1 (en) 2011-08-12
PE20140806A1 (es) 2014-07-17
SG10201608305SA (en) 2016-11-29
CL2009001001A1 (es) 2010-05-14
BRPI0907701A2 (pt) 2019-12-10
IL208555A (en) 2017-09-28
PT2283041E (pt) 2015-11-24
US20140212433A1 (en) 2014-07-31
US9676868B2 (en) 2017-06-13
CN103724433A (zh) 2014-04-16
CN102066419A (zh) 2011-05-18
MX2010011342A (es) 2010-12-06
US20140065137A1 (en) 2014-03-06
PH12014500519B1 (en) 2019-06-28
RS54405B1 (sr) 2016-04-28
HK1245812A1 (en) 2018-08-31
US20190185579A1 (en) 2019-06-20
JP2013231045A (ja) 2013-11-14
US8273352B2 (en) 2012-09-25
AU2009241348B2 (en) 2012-11-15
AR086272A2 (es) 2013-12-04
KR20130084330A (ko) 2013-07-24
CA2720853C (fr) 2015-12-29
IL266039A (en) 2019-06-30
US8614306B2 (en) 2013-12-24
EP2283041A1 (fr) 2011-02-16
CY1116982T1 (el) 2017-04-05
DK2283041T3 (da) 2015-12-07
ECSP10010637A (es) 2010-12-30
RU2010148423A (ru) 2012-06-10
AR071510A1 (es) 2010-06-23
JP5931008B2 (ja) 2016-06-08
NZ603492A (en) 2014-05-30
PE20091783A1 (es) 2009-12-04
CO6331346A2 (es) 2011-10-20
SG189756A1 (en) 2013-05-31
EP2283041B1 (fr) 2015-09-02
TW201819418A (zh) 2018-06-01
TW200944234A (en) 2009-11-01
RU2488594C2 (ru) 2013-07-27
US20160145349A1 (en) 2016-05-26
EP3002295A1 (fr) 2016-04-06
CN103724433B (zh) 2015-11-18
TWI558413B (zh) 2016-11-21
PH12014500519A1 (en) 2017-12-11
JP5636359B2 (ja) 2014-12-03
SI2283041T1 (sl) 2015-12-31
KR101322027B1 (ko) 2013-10-30
IL253014A0 (en) 2017-08-31
CN102066419B (zh) 2014-07-02
KR20110004451A (ko) 2011-01-13
US20120328613A1 (en) 2012-12-27
ZA201301709B (en) 2023-01-25
CL2018000537A1 (es) 2018-07-20
MY172433A (en) 2019-11-25
HK1193111A1 (zh) 2014-09-12
IL208555A0 (en) 2010-12-30
TW201437230A (zh) 2014-10-01
WO2009134711A8 (fr) 2010-10-21
TWI616456B (zh) 2018-03-01
NZ588457A (en) 2012-12-21
HRP20151259T1 (hr) 2015-12-18
CR11817A (es) 2011-01-13
MY162350A (en) 2017-06-15
US20180100024A1 (en) 2018-04-12
EP3235829A1 (fr) 2017-10-25
HUE026349T2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
MA34120B1 (fr) Composition pharmaceutique
MA29439B1 (fr) Derives d'uree d'heteroaryle utilises pour inhiber chk1
MA30252B1 (fr) Vaccin therapeutique
MA45655A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
TN2009000551A1 (fr) Nouveaux composes chimiques
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA30632B1 (fr) Anticorps humanisé
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
MA33726B1 (fr) Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation
MA32621B1 (fr) Traitement de maladie auto-immune et inflammatoire
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MY162350A (en) Humanized anti-factor d antibodies and uses thereof
MA33815B1 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
TNSN07401A1 (fr) Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA29366B1 (fr) Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines